Sionna Therapeutics [SION] vs Kymera Therapeutics [KYMR] Detailed Stock Comparison
Sionna Therapeutics
NASDAQ
Loading...
Kymera Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 17 vital metrics comparison: Sionna Therapeutics wins in 9 metrics, Kymera Therapeutics wins in 4 metrics, with 1 ties. Sionna Therapeutics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sionna Therapeutics | Kymera Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -16.51 | -14.67 | Sionna Therapeutics |
| Price-to-Book Ratio | 3.15 | 3.16 | Sionna Therapeutics |
| Debt-to-Equity Ratio | 2.75 | 8.82 | Sionna Therapeutics |
| PEG Ratio | 4.35 | -0.23 | Kymera Therapeutics |
| EV/EBITDA | -9.26 | -8.30 | Sionna Therapeutics |
| Profit Margin (TTM) | 0.00% | 0.00% | Tie |
| Operating Margin (TTM) | 0.00% | -736.82% | Sionna Therapeutics |
| Return on Equity | 37.68% | -33.26% | Sionna Therapeutics |
| Return on Assets (TTM) | -33.21% | -19.92% | Kymera Therapeutics |
| Free Cash Flow (TTM) | $-52.81M | $-207.34M | Sionna Therapeutics |
| 1-Year Return | -4.00% | -4.16% | Sionna Therapeutics |
| Price-to-Sales Ratio (TTM) | N/A | 69.58 | N/A |
| Enterprise Value | $806.02M | $2.53B | Kymera Therapeutics |
| EV/Revenue Ratio | N/A | 56.61 | N/A |
| Revenue per Share (TTM) | $0 | $1 | Kymera Therapeutics |
| Earnings per Share (Diluted) | $-1.72 | $-3.60 | Sionna Therapeutics |
| Beta (Stock Volatility) | N/A | 2.18 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Sionna Therapeutics vs Kymera Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sionna Therapeutics | 4.08% | -2.52% | 36.91% | 49.72% | 45.63% | -4.00% |
| Kymera Therapeutics | 3.10% | 5.61% | 1.26% | -8.71% | 37.26% | 6.41% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sionna Therapeutics | -4.00% | -4.00% | -4.00% | -4.00% | -4.00% | -4.00% |
| Kymera Therapeutics | -4.16% | 48.25% | 39.50% | 30.82% | 30.82% | 30.82% |
Performance & Financial Health Analysis: Sionna Therapeutics vs Kymera Therapeutics
| Metric | SION | KYMR |
|---|---|---|
| Market Information | ||
| Market Cap | $1.12B | $3.19B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 229,087 | 657,980 |
| 90 Day Avg. Volume | 193,736 | 659,833 |
| Last Close | $24.00 | $43.51 |
| 52 Week Range | $7.26 - $26.50 | $19.44 - $53.27 |
| % from 52W High | -9.43% | -18.32% |
| All-Time High | $26.50 (Aug 28, 2025) | $91.92 (Dec 28, 2020) |
| % from All-Time High | -9.43% | -52.67% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | -0.55% |
| Quarterly Earnings Growth | N/A | -0.55% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | 0.00% | -7.37% |
| Return on Equity (TTM) | 0.38% | -0.33% |
| Debt to Equity (MRQ) | 2.75 | 8.82 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.62 | $13.77 |
| Cash per Share (MRQ) | $5.95 | $9.31 |
| Operating Cash Flow (TTM) | $-63,908,000 | $-251,008,000 |
| Levered Free Cash Flow (TTM) | $-61,688,000 | $-153,841,376 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Sionna Therapeutics vs Kymera Therapeutics
| Metric | SION | KYMR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -16.51 | -14.67 |
| Forward P/E | -11.58 | -13.99 |
| PEG Ratio | 4.35 | -0.23 |
| Price to Sales (TTM) | N/A | 69.58 |
| Price to Book (MRQ) | 3.15 | 3.16 |
| Market Capitalization | ||
| Market Capitalization | $1.12B | $3.19B |
| Enterprise Value | $806.02M | $2.53B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 56.61 |
| Enterprise to EBITDA | -9.26 | -8.30 |
| Risk & Other Metrics | ||
| Beta | N/A | 2.18 |
| Book Value per Share (MRQ) | $7.62 | $13.77 |
Financial Statements Comparison: Sionna Therapeutics vs Kymera Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SION | KYMR |
|---|---|---|
| Revenue/Sales | $0 | $11.48M |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | $13.67M | $78.39M |
| Operating Income (EBIT) | $-19.66M | $-84.56M |
| EBITDA | $-19.23M | $-74.42M |
| Pre-Tax Income | $-16.48M | $-76.61M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $-16.48M | $-76.61M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SION | KYMR |
|---|---|---|
| Cash & Equivalents | $82.70M | $89.97M |
| Total Current Assets | $273.68M | $500.95M |
| Total Current Liabilities | $9.53M | $58.99M |
| Long-Term Debt | $8.38M | $73.09M |
| Total Shareholders Equity | $351.77M | $786.23M |
| Retained Earnings | $-197.57M | $-820.19M |
| Property, Plant & Equipment | $9.16M | $18.88M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SION | KYMR |
|---|---|---|
| Operating Cash Flow | $-10.71M | $-67.71M |
| Capital Expenditures | $-86,000 | $-467,000 |
| Free Cash Flow | $-16.37M | $-79.62M |
| Debt Repayment | N/A | $-277,000 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SION | KYMR |
|---|---|---|
| Shares Short | 3.60M | 7.61M |
| Short Ratio | 22.40 | 11.93 |
| Short % of Float | 0.14% | 0.13% |
| Average Daily Volume (10 Day) | 229,087 | 657,980 |
| Average Daily Volume (90 Day) | 193,736 | 659,833 |
| Shares Outstanding | 42.44M | 64.89M |
| Float Shares | 11.04M | 46.96M |
| % Held by Insiders | 0.07% | 0.02% |
| % Held by Institutions | 0.98% | 1.10% |
Dividend Analysis & Yield Comparison: Sionna Therapeutics vs Kymera Therapeutics
| Metric | SION | KYMR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |